Phase I – Bioequivalence

302 trials 14 recruiting

Filter these 302 trials by condition, country, sponsor and more.

Open in Search →

Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-514448-10-00 No medical condition. 2024-08-09
A study to learn how zilucoplan moves throughout the body over time when given in 2 different ways in healthy adults Ended

2023-508388-64-00 Healthy Volunteers 2024-08-05
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended

2024-513752-15-00 No medical condition. 2024-08-01
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosam… Ended

2023-507991-32-00 Epileptic seizures 2024-07-25
Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended

2024-513751-32-00 No medical condition. 2024-07-24
Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2023-509422-21-00 No medical condition. 2024-07-17
Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjects Ended

2023-504901-34-00 No medical condition. 2024-07-15
Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose ad… Ended

2024-512310-18-00 diabetes 2024-07-08
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512910-16-00 No medical condition. 2024-07-03
Bioequivalence clinical trial of two formulations of dapagliflozin. Ended

2023-506561-62-00 Healthy volunteers 2024-07-01
Conducting a quality study of the medicinal product - Vortioxetine Ended

2023-509946-36-00 No therapeutic indication in the current trial with hea 2024-06-29
A study in healthy people to compare two different Sifrol® tablets Ended

2024-510764-23-00 Pharmacokinetic trial 2024-06-27
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditio… Ended

2024-512853-26-00 No medical condition 2024-06-27
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsal… Ended

2024-513665-40-00 not applicable (submitted trial is a bioequivalence in 2024-06-25
Bioequivalence clinical trial of two formulations of linagliptin Ended

2023-506562-31-00 Healthy volunteers 2024-06-14
Bioequivalence clinical trial of two formulations of edoxaban. Ended

2024-510795-20-00 Healthy volunteers 2024-06-11
A study in healthy people to compare how 2 different low dose formulations of BI 1015550 are taken up in the body Ended

2023-509951-15-00 Pharmacokinetic trial 2024-06-06
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Ver… Ended

2023-509749-11-00 Healthy volunteers 2024-06-05
Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to… Ended

2024-512311-41-00 Parkinson´s disease 2024-06-03
A randomized, two-way, crossover, two parallel groups study to compare the bioavailability of 150 mg and 300 mg trazodone hydrochloride tabl… Ended

2024-511612-24-00 Intended indication: Major Depressive Disorders with an 2024-05-31
A Single Dose, Two – stage, Fasting State, Bioequivalence Study of Rifaximin 200 mg, film-coated tablets (Antibiotice S.A.) vs. Normix® 200 … Ended

2024-510671-38-00 healthy subjects 2024-05-26
A study in healthy people to compare how 2 different high dose formulations of BI 1015550 are taken up in the body Ended

2023-509950-67-00 Pharmacokinetic trial 2024-05-23
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions Ended

2024-512857-25-00 No medical condition. 2024-05-21
An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Val… Ended

2024-511570-77-00 not applicable (submitted trial is a bioavailability st 2024-05-13